Ajax Health has announced the receipt of a $90 million investment into Cortex, a MedTech it has developed for treating atrial fibrillation (AFib).

Noting that AFib is the most common heart rhythm disorder, affecting more than 30 million patients worldwide, the company plans to develop an integrated mapping and ablation solution for its treatment.

Cortex will focus on developing diagnostic and pulsed field ablation catheters with a comprehensive mapping and navigation solution powered by Ablacon‘s innovative Electrographic Flow (EGF) mapping technology.

Ajax Health added that EGF mapping allows physicians to detect AFib sources and is designed to support personalised ablation therapy to potentially improve outcomes.

“Cortex’s vision is to enable more intelligent AFib treatment,” said Duke Rohlen, chief executive of Ajax Health and Cortex. “We are developing solutions that prioritise precision, simplicity, and efficiency to simultaneously improve patient outcomes and lower procedural cost.”

The investment is being led by private equity company KKR And Hellman & Friedman.

“Duke Rohlen and the Ajax team have cultivated an exceptional ecosystem of engineers and clinical experts with a clear plan to bring impactful new technology to clinical settings,” said Ali Satvat, partner, co-head of Americas health care and global head of health care strategic growth at KKR. “We are pleased to continue our long-standing strategic partnership with Duke and join with a strong investor group to support Cortex as it pursues improved outcomes for cardiac arrhythmia patients.”

---